Brief ReportBuspirone for the Treatment of Generalized Anxiety Disorder in Down Syndrome: 3 CasesHowe, Yamini J. MD*,†,‡; Thom, Robyn P. MD*,†,§; Notson, Erin E. OTR/L‖; McDougle, Christopher J. MD*,†,§; Palumbo, Michelle L. MD*,†,‡ Author Information *Massachusetts General Hospital, Boston, MA; †Lurie Center for Autism, Lexington, MA; ‡Department of Pediatrics, Harvard Medical School, Boston, MA; §Department of Psychiatry, Harvard Medical School, Boston, MA; ‖Oak Creek Franklin Joint School District, Oak Creek, WI. Address for reprints: Christopher J. McDougle, MD, Lurie Center for Autism, 1 Maguire Rd, Lexington, MA, 02421; e-mail: [email protected]. This work was funded, in part, by the Nancy Lurie Marks Family Foundation. Disclosure: The authors declare no conflict of interest. Journal of Developmental & Behavioral Pediatrics 43(1):p 38-43, January 2022. | DOI: 10.1097/DBP.0000000000000970 Buy Metrics Abstract Objective: Reports on the pharmacologic treatment of anxiety, including generalized anxiety disorder (GAD), in individuals with Down syndrome (DS) are lacking. Methods: We present the case histories of 1 adolescent and 2 young adults with DS and the treatment course of comorbid GAD with buspirone. Results: Treatment with buspirone was safe and well-tolerated and resulted in sustained improvement in symptoms of anxiety for a minimum of 2 years in all 3 cases. Conclusion: Buspirone's generally benign adverse effect profile makes it well suited for treating anxiety in individuals with DS in light of their common medical comorbidities. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.